"
Team:Washington/Project/Safety/Secretion
From 2010.igem.org
(Difference between revisions)
| Line 25: | Line 25: | ||
</html> | </html> | ||
<!---------------------------------------PAGE CONTENT GOES BELOW THIS----------------------------------------> | <!---------------------------------------PAGE CONTENT GOES BELOW THIS----------------------------------------> | ||
| - | + | Our work on Gram-negative Therapeutics was done only on non-pathogenic strains. We used the Type VI Secretion System from ''Pseudomonas aeruginosa'' PAO1. All modifications and testing of plasmids and fosmids were in non-pathogenic E. Coli strains, namely EPI300, SW102, and BL21. And Team Tse2's strain...MPI?? | |
| - | + | ||
<!---------------------------------------PAGE CONTENT GOES ABOVE THIS----------------------------------------> | <!---------------------------------------PAGE CONTENT GOES ABOVE THIS----------------------------------------> | ||
Revision as of 19:14, 7 September 2010
Our work on Gram-negative Therapeutics was done only on non-pathogenic strains. We used the Type VI Secretion System from Pseudomonas aeruginosa PAO1. All modifications and testing of plasmids and fosmids were in non-pathogenic E. Coli strains, namely EPI300, SW102, and BL21. And Team Tse2's strain...MPI??
